| Cell line name |
CAL-27 2B1 |
|---|
| Synonyms |
Cal27 2B1; 2B1 |
|---|
| Accession |
CVCL_C0RK |
|---|
| Resource Identification Initiative |
To cite this cell line use: CAL-27 2B1 (RRID:CVCL_C0RK) |
|---|
| Comments |
Population: Caucasian.
Transfected with: HGNC; 6156; ITGB3.
Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723. |
|---|
| Sequence variations |
- Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line).
|
|---|
| Disease |
Tongue adenosquamous carcinoma (NCIt: C173807) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_1107 (CAL-27) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
56Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=27108184; DOI=10.1016/j.bbamcr.2016.04.019
Stojanovic N., Brozovic A., Majhen D., Bosnar M.H., Fritz G., Osmak M., Ambriovic-Ristov A.
Integrin alphavbeta3 expression in tongue squamous carcinoma cells Cal27 confers anticancer drug resistance through loss of pSrc(Y418).
Biochim. Biophys. Acta 1863:1969-1978(2016) PubMed=34977030; DOI=10.3389/fcell.2021.786758
Tadijan A., Humphries J.D., Samarzija I., Stojanovic N., Zha J.-Z., Culjak K., Tomic M., Paradzik M., Nestic D., Kang H., Humphries M.J., Ambriovic-Ristov A.
The tongue squamous carcinoma cell line Cal27 primarily employs integrin alpha6beta4-containing type II hemidesmosomes for adhesion which contribute to anticancer drug sensitivity.
Front. Cell Dev. Biol. 9:786758.1-786758.17(2021) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q112929360
|
|---|
| Proteomic databases |
PRIDE; PXD028810
|
|---|
| Entry history |
|---|
| Entry creation | 23-Jun-2022 |
|---|
| Last entry update | 29-Jun-2023 |
|---|
| Version number | 5 |
|---|